Report PDF 1

LPL - PSC-SHALIMAR BAGH

Shop No. A1/BQ Market,

Shalimar Bagh, De lhi-110088.

DELHI

Name

A/c Status

Lab No.

Ref By :

Gender: Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:15PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO

Mrs. SHUCHI AGGARWAL

Test Name Results Units Bio. Ref. Interval

COMPREHENSIVE WELLNESS ADVANCE

LIPID PROFILE, BASIC, SERUM

(Spectrophotometry, Calculated)

204.00Cholesterol Total <200.00 mg/dL

80.00Triglycerides <150.00 mg/dL

70.00HDL Cholesterol 40.00 - 60.00 mg/dL

118.00LDL Cholesterol <100.00 mg/dL

16.00VLDL Cholesterol <30.00 mg/dL

134.00Non-HDL Cholesterol mg/dL

Interpretation

--------------------------------------------------------------------------| NCEP RECOMMENDATIONS| TOTAL CHOLESTEROL | TRIGLYCERIDE |LDL CHOLESTEROL || | in mg/dL | in mg/dL |in mg/dL ||---------------------|-------------------|--------------|-----------------|| Optimal | <200 | <150 | <100 ||---------------------|-------------------|--------------|-----------------|| Above Optimal | - | - | 100-129 ||---------------------|-------------------|--------------|-----------------|| Borderline High | 200-239 | 150-199 | 130-159 ||---------------------|-------------------|--------------|-----------------|| High | >=240 | 200-499 | 160-189 ||---------------------|-------------------|--------------|-----------------|| Very High | - | >=500 | >=190 | --------------------------------------------------------------------------

Note

1. Measurements in the same patient can show physiological & analytical variations. Three serial samples

1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status.

Selective screening of children above the age of 2 years with a family history of premature

cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. NCEP identifies elevated Triglycerides as an independent risk factor for Coronary Heart Disease (CHD).

4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to

participate in reverse cholesterol transport, the process by which cholesterol is eliminated from

peripheral tissues.

5. ATP III guidelines uses LDL Cholesterol as the primary target for cholesterol lowering therapy. Note that

major risk factors can modify LDL goals.

NON HDL CHOLESTEROL

-----------------------------------------------------------------------| RISK CATEGORY | LDL GOAL (mg/dL) | NON HDL GOAL (mg/dL) ||----------------------|-------------------------|----------------------|| CHD & CHD risk | < 100 | < 130 || equivalent (10 year | | |

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 4)

.

Page 1 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender: Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:15PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO


Test Name Results Units Bio. Ref. Interval| risk for CHD > 20 %) | | | -----------------------------------------------------------------------

-----------------------------------------------------------------------| Multiple (2+) Risk | < 130 | < 160 || Factors and 10 year | | || risk < or = 20% | | ||----------------------|-------------------------|----------------------|| 0-1 Risk factor | < 160 | <190 | -----------------------------------------------------------------------

Comments

ATP III suggested the addition of Non HDL Cholesterol (Total Cholesterol - HDL Cholesterol) as an indicator of

all atherogenic lipoproteins (mainly LDL & VLDL). The Non HDL Cholesterol is used as a secondary target of

therapy in persons with triglycerides >=200 mg/dL. The goal for Non HDL Cholesterol in those with increased

triglyceride is 30 mg/dL above that set for LDL Cholesterol.

For calculation of CHD risk, history of smoking, any medication for hypertension & current blood pressure

levels are required.

LIVER & KIDNEY PANEL, SERUM

(Spectrophotometry, Indirect ISE)

24.00Urea 17.00 - 43.00 mg/dL

0.66Creatinine 0.51 - 0.95 mg/dL

4.30Uric Acid 2.60 - 6.00 mg/dL

16AST (SGOT) <35 U/L

11ALT (SGPT) <35 U/L

16GGTP <38 U/L

59Alkaline Phosphatase (ALP) 30 - 120 U/L

0.66Bilirubin Total 0.30 - 1.20 mg/dL

0.13Bilirubin Direct <0.20 mg/dL

0.53Bilirubin Indirect <1.10 mg/dL

6.40Total Protein 6.40 - 8.30 g/dL

3.63Albumin 3.50 - 5.20 g/dL

1.31A : G Ratio 0.90 - 2.00

8.30Calcium, Total 8.80 - 10.60 mg/dL

3.10Phosphorus 2.40 - 4.40 mg/dL

133.00Sodium 136.00 - 146.00 mEq/L

4.28Potassium 3.50 - 5.10 mEq/L

102.00Chloride 101.00 - 109.00 mEq/L


.

Page 2 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender: Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:15PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO



GLUCOSE, FASTING (F) AND POST MEAL, PLASMA

(Hexokinase)

85.00Glucose Fasting 70.00 - 100.00 mg/dL

78.00Glucose (PP) 70.00 - 140.00 mg/dL


.

Page 3 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender:Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:20PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO



URINE EXAMINATION, ROUTINE; URINE, R/E

(Automated Strip Test, Microscopy)

Physical

Colour Pale yellowLight Yellow

Specific Gravity 1.001 - 1.0301.010

pH 5.0 - 8.07.5

Chemical

Proteins NilNil

Glucose NilNil

Ketones NilNil

Bilirubin NilNil

Urobilinogen NormalNormal

Leucocyte Esterase NegativePositive

Nitrite NegativeNegative

Microscopy

R.B.C. NegativeNegative

Pus Cells 0-5 WBC / hpf5-7 WBC/HPF

Epithelial Cells Few+(in small numbers)

Casts Nil /lpfNil

Crystals NilNil

Others -Amorphous Phosphate :

+

PatientReportSCSuperPanel.URINE_EXAMINATION_SC (Version: 4)

.

Page 4 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender:Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:24PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO



HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD

(HPLC, NGSP certified)

4.90 %

Interpretation ------------------------------------------------------------------------------- | As per American Diabetes Association (ADA) ||-------------------------------------------------------------------------------| | Reference Group | HbA1c in % ||-------------------------------|-----------------------------------------------| | Non diabetic adults >=18 years| <5.7 | |-------------------------------|-----------------------------------------------| | At risk (Prediabetes) | 5.7 - 6.4 | |-------------------------------|-----------------------------------------------| | Diagnosing Diabetes | >= 6.5 ||-------------------------------|-----------------------------------------------|| Therapeutic goals for glycemic| Age > 19 years || control | . Goal of therapy: < 7.0 || | . Action suggested: > 8.0 || | || | Age < 19 years || | . Goal of therapy: <7.5 | -------------------------------------------------------------------------------

Note: 1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a

diabetic patient who is recently under good control may still have a high concentration of

HbA1c. Converse is true for a diabetic previously under good control but now poorly

controlled .

2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long

life expectancy and no significant cardiovascular disease. In patients with significant

complications of diabetes, limited life expectancy or extensive co-morbid conditions,

targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better

indicator of long term glycemic control as compared to blood and urinary glucose determinations.

ADA criteria for correlation between HbA1c & Mean plasma glucose levels

--------------------------------------- | HbA1c(%) | Mean Plasma Glucose (mg/dL)| |----------|----------------------------| | 6 | 126 | |----------|----------------------------| | 7 | 154 | |----------|----------------------------| | 8 | 183 | |----------|----------------------------| | 9 | 212 |

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 5)

.

Page 5 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender:Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:24PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO


Test Name Results Units Bio. Ref. Interval |----------|----------------------------| | 10 | 240 | |----------|----------------------------| | 11 | 269 | |----------|----------------------------| | 12 | 298 | ---------------------------------------

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 5)

.

Page 6 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender: Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:28PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO



HEMOGRAM

(Electrical Impendance & VCS, Capillary photometry)

Hemoglobin 11.50 - 15.00 g/dL11.80

Packed Cell Volume (PCV) 36.00 - 46.00 %35.60

RBC Count 3.80 - 4.80 mill/mm34.19

MCV 80.00 - 100.00 fL85.00

MCH 27.00 - 32.00 pg28.30

MCHC 32.00 - 35.00 g/dL33.20

Red Cell Distribution Width (RDW) 11.50 - 14.50 %14.10

Total Leukocyte Count (TLC) 4.00 - 10.00 thou/mm35.60

Differential Leucocyte Count (DLC)

40.00 - 80.00 Segmented Neutrophils %61.50

20.00 - 40.00 Lymphocytes %24.40

2.00 - 10.00 Monocytes %9.00

1.00 - 6.00 Eosinophils %4.60

<2.00 Basophils %0.50

Absolute Leucocyte Count

2.00 - 7.00 Neutrophils thou/mm33.44

1.00 - 3.00 Lymphocytes thou/mm31.37

0.20 - 1.00 Monocytes thou/mm30.50

0.02 - 0.50 Eosinophils thou/mm30.26

0.01 - 0.10 Basophils thou/mm30.03

Platelet Count 150.00 - 450.00 thou/mm3302.0

ESR 0 - 20 mm/hr17

Note

1. As per the recommendation of International council for Standardization in Hematology, the differential

leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of

blood

2. Test conducted on EDTA whole blood

PatientReportSCSuperPanel.CBC_SC (Version: 4)

.

Page 7 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender:Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:31PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO



CARDIO C-REACTIVE PROTEIN (hsCRP), SERUM

(Immunoturbidimetry)

1.30 mg/L <1.00

Interpretation

--------------------------------------------------------------| CARDIO CRP IN mg/L | CARDIOVASCULAR RISK ||-----------------------|--------------------------------------|| <1 | Low ||-----------------------|--------------------------------------|| 1-3 | Average ||-----------------------|--------------------------------------|| 3-10 | High ||-----------------------|--------------------------------------|| >10 | Persistent elevation may represent || | Non cardiovascular inflammation | --------------------------------------------------------------

Note: To assess vascular risk, it is recommended to test hsCRP levels 2 or more weeks apart and

calculate the average

Comments

High sensitivity C Reactive Protein (hsCRP) significantly improves cardiovascular risk assessment as it is a

strongest predictor of future coronary events. It reveals the risk of future Myocardial infarction and Stroke

among healthy men and women, independent of traditional risk factors. It identifies patients at risk of first

Myocardial infarction even with low to moderate lipid levels. The risk of recurrent cardiovascular events also

correlates well with hsCRP levels. It is a powerful independent risk determinant in the prediction of incident

Diabetes.

THYROID PROFILE, FREE, SERUM

(CLIA)

T3, Free; FT3 2.84 pg/mL 2.30 - 4.20

T4, Free; FT4 1.00 ng/dL 0.89 - 1.76

TSH, Ultrasensitive 2.162 uIU/mL 0.550 - 4.780

Reference Ranges for pregnancy -------------------------------------------------------------------------| PREGNANCY | REFERENCE RANGE for TSH in | REFERENCE |REFERENCE || | uIU/mL (As per American | RANGE for FT3|RANGE for FT4 || | Thyroid Association) | in pg/mL |in ng/dL ||-------------|----------------------------|--------------|---------------||1st Trimester| 0.100 - 2.500 | 2.11-3.83 |0.70 -2.00 ||-------------|----------------------------|--------------|---------------||2st Trimester| 0.200 - 3.000 | 1.96-3.38 |0.50 -1.60 ||-------------|----------------------------|--------------|---------------||3st Trimester| 0.300 - 3.000 | 1.96-3.38 |0.50 -1.60 | --------------------------------------------------------------------------

Note

1. TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 5)

.

Page 8 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender:Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:31PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO



minimum between 6-10 pm. The variation is of the order of 50%. hence time of the day has influence

on the measured serum TSH concentrations.

2. TSH Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in

some individuals

Clinical Use

· Primary Hypothyroidism

· Hyperthyroidism

· Hypothalamic - Pituitary hypothyroidism

· Inappropriate TSH secretion

· Nonthyroidal illness

· Autoimmune thyroid disease

· Pregnancy associated thyroid disorders

· Thyroid dysfunction in infancy and early childhood

VITAMIN D, 25 - HYDROXY, SERUM

(CLIA)

34.39 nmol/L

Interpretation -------------------------------------------------------------| LEVEL | REFERENCE RANGE | COMMENTS || | IN nmol/L | ||---------------|-----------------|---------------------------|| Deficient | < 50 | High risk for developing || | | bone disease ||---------------|-----------------|---------------------------|| Insufficient | 50-74 | Vitamin D concentration || | | which normalizes || | | Parathyroid hormone || | | concentration ||---------------|-----------------|---------------------------|| Sufficient | 75-250 | Optimal concentration | | | | for maximal health benefit||---------------|-----------------|---------------------------|| Potential | >250 | High risk for toxic || intoxication | | effects | -------------------------------------------------------------

Note

· The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.

· 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.

· Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.

· It shows seasonal variation, with values being 40-50% lower in winter than in summer.

· Levels vary with age and are increased in pregnancy.


.

Page 9 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender:Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:31PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO



· The recommended test for evaluation of 25 Hydroxy Vitamin D is by LC-MS/MS

Comments

Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency

in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and

Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major

circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

Decreased Levels

· Inadequate exposure to sunlight

· Dietary deficiency

· Vitamin D malabsorption

· Severe Hepatocellular disease

· Drugs like Anticonvulsants

· Nephrotic syndrome

Increased levels

Vitamin D intoxication

IRON STUDIES, SERUM

(Spectrophotometry)

Iron 27.00 µg/dL 50.00 - 170.00

Total Iron Binding Capacity 330.00 µg/dL 250.00 - 425.00

Transferrin Saturation 8.18 % 15.00 - 50.00

Comments

Iron is an essential trace mineral element which forms an important component of hemoglobin,

metallocompounds and Vitamin A. Deficiency of iron, leads to microcytic hypochromic anemia. The toxic

effects of iron are deposition of iron in various organs of the body and hemochromatosis.

Total Iron Binding capacity (TIBC) is a direct measure of the protein Transferrin which transports iron from

the gut to storage sites in the bone marrow. In iron deficiency anemia, serum iron is reduced and TIBC

increases.

Transferrin Saturation occurs in Idiopathic hemochromatosis and Transfusional hemosiderosis where no

unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital

deficiency of Transferrin.

VITAMIN B12; CYANOCOBALAMIN, SERUM

(CLIA)

231.00 pg/mL 211.00 - 911.00

Note: To differentiate vitamin B12 & folate deficiency, measurement of Methyl malonic acid in urine & serum


.

Page 10 of 11




DELHI

Name

A/c Status

Lab No.

Ref By :

Gender:Age:

Report Status

Reported

Received

Collected

P

6/6/2015 6:48:31PM

:

:

:

:

:

:

: Final

35 Years

6/6/2015 10:18:00AM

6/6/2015 10:22:39AM120968433 Female

DR ANIL GANJOO



Homocysteine level is suggested

Comments

Vitamin B12 performs many important functions in the body, but the most significant function is to act as

co-enzyme for reducing ribonucleotides to deoxyribonucleotides, a step in the formation of genes. Inadequate

dietary intake is not the commonest cause for cobalamine deficiency. The most common cause is

malabsorption either due to atrophy of gastric mucosa or diseases of terminal ileum. Cobalamine deficiency

leads to Megaloblastic anemia and demyelination of large nerve fibres of spinal cord. Normal body stores are

sufficient to last for 3-6 years. Sources of Vitamin B12 are liver, shellfish, fish, meat, eggs, milk, cheese &

yogurt.

Decreased Levels

· Lack of Intrinsic factor: Total or partial gastrectomy, Atrophic gastritis, Intrinsic factor antibodies

· Malabsorption: Regional ileitis, resected bowel, Tropical Sprue, Celiac disease, pancreatic

insufficiency, bacterial overgrowth & achlorhydria

· Loss of ingested vitamin B12: fish tapeworm

· Dietary deficiency: Vegetarians

· Congenital disorders: Orotic aciduria & transcobalamine deficiency

· Increased demand: Pregnancy specially last trimester

Increased Levels

Chronic renal failure, Congestive heart failure, Acute & Chronic Myeloid Leukemia, Polycythemia vera,

Carcinomas with liver metastasis, Liver disease, Drug induced cholestasis & Protein malnutrition

Dr. Nimmi Kansal

MD (Biochemistry)

HOD Biochem & IA

Dr. Shalabh Malik

MD (Microbiology)

HOD Micro & Clinical Path

Dr. Sushrut Pownikar

DNB (Pathology)

HOD Hemat & Imm

-------------------------------End of report --------------------------------


.

Page 11 of 11

Documents

Report PDF 1